Your browser doesn't support javascript.
loading
Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy.
Lindner, Andrea Katharina; Lackner, Felizian; Tymoszuk, Piotr; Barth, Dominik Andreas; Seeber, Andreas; Kocher, Florian; Toth, Bettina; Hochleitner, Margarethe; Pichler, Martin; Pichler, Renate.
Afiliación
  • Lindner AK; Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.
  • Lackner F; Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.
  • Tymoszuk P; Data Analytics As a Service Tirol, Innsbruck, Austria.
  • Barth DA; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Seeber A; Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.
  • Kocher F; Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.
  • Toth B; Department of Gynecological Endocrinology and Reproductive Medicine, Medical University Innsbruck, Innsbruck, Austria.
  • Hochleitner M; Department of Internal Medicine, Gender Medicine Unit, Medical University of Innsbruck, Innsbruck, Austria.
  • Pichler M; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Pichler R; Translational Oncology, University Hospital of Augsburg, Augsburg, Germany.
Biol Sex Differ ; 14(1): 38, 2023 06 05.
Article en En | MEDLINE | ID: mdl-37277835
Urothelial carcinoma (UC) presents as aggressive disease with a greater incidence in men, yet a more aggressive course of disease in women. Patients with metastatic UC receive a chemotherapy regimen as the gold standard, based on an included platin substance. In the case of having contraindications to chemotherapy, checkpoint immunotherapy, priming the immune system to the tumor, is the treatment of choice. Furthermore, immunotherapy is used as second line therapy in progressive disease after chemotherapy and as maintenance therapy in stable tumor conditions after completing the chemotherapy regimen.Evidence shows that sex hormones of the hypothalamus­hypophysis axis influence development and course of UC. The sex hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH) stimulate estrogen (E2) production with a negative feedback function on the LH and FSH secretion. High levels of E2 present with a protective effect against UC. Sex has furthermore shown to predict potential response to immunotherapy. This study therefore focused on monitoring and correlating changes of sex hormone levels in 28 patients during therapy with checkpoint inhibitors.This first study assessing changes in sex hormones and the influence of baseline sex hormone values on survival in UC shows that responders to immunotherapy had significantly increased FSH levels. FSH furthermore increased in male patients receiving second line immunotherapy. High values of LH and a high LH/FSH ratio at baseline correlated with better overall survival in female patients. High E2 levels were indicative of better survival in male patients. The study results represent first suggestive prognostic and predictive results to the response of immunotherapy in UC.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Carcinoma de Células Transicionales Tipo de estudio: Prognostic_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: Biol Sex Differ Año: 2023 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Carcinoma de Células Transicionales Tipo de estudio: Prognostic_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: Biol Sex Differ Año: 2023 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Reino Unido